Courage Against Cancer
At Courage Against Cancer (CAC), we understand why stories like Joe Tippens’ capture the hearts and hopes of people facing a devastating diagnosis. When conventional medicine feels uncertain, a compelling personal recovery story can feel like a lifeline.
At Courage Against Cancer (CAC), we believe every patient deserves evidence-based answers to the most pressing questions surrounding emerging therapies — including the question driving significant research interest today: What does preclinical research show about fenbendazole and colorectal cance…
At Courage Against Cancer (CAC), we believe cancer patients deserve honest, evidence-based answers to the most pressing question surrounding fenbendazole and colorectal cancer: does promising laboratory data actually mean the compound works the same way in the human body? The short answer is — n…
At Courage Against Cancer (CAC), we believe every patient deserves evidence-based answers to the question of whether fenbendazole genuinely treats colorectal cancer — and that means honestly examining what stories like Joe Tippens’s can and cannot tell us.
This article from Courage Against Cancer evaluates the potential of fenbendazole, a veterinary drug, as a treatment for human colorectal cancer. Despite promising preclinical evidence, there are no conclusive human trials proving its efficacy. Patients are urged to discuss its use with oncologists, as risks such as liver toxicity exist.
The article from Courage Against Cancer discusses Joe Tippens, whose recovery from small cell lung cancer was linked to fenbendazole, a veterinary dewormer. It emphasizes that his case lacks clinical validation and critical context, such as concurrent immunotherapy, highlighting the importance of distinguishing personal narratives from scientific evidence in cancer treatment discussions.
The article from Courage Against Cancer emphasizes the importance of critically evaluating cancer treatment claims, particularly viral studies like the 2026 Hulscher et al. ivermectin-mebendazole paper. It provides a structured framework for assessing study validity, distinguishing between preclinical and clinical evidence, and understanding potential conflicts of interest to make informed treatment decisions.
Courage Against Cancer clarifies the distinction between the legitimate preclinical research conducted by the NCI on ivermectin and the controversial Hulscher observational study. The latter’s findings are compromised due to bias and conflicts of interest. Conflating the two may mislead patients, potentially exploiting their vulnerability and delaying effective treatments.